The authors used human and rat muscle to study the mechanism of statin myopathy and its interaction with exercise. 
SUMMARY
This study aimed to identify a mechanism for statin-induced myopathy that explains its prevalence and selectivity for skeletal muscle, and to understand its interaction with moderate exercise. Statin-associated adverse muscle symptoms reduce adherence to statin therapy; this limits the effectiveness of statins in reducing cardiovascular risk. The issue is further compounded by perceived interactions between statin treatment and exercise. This study examined muscles from individuals taking statins and rats treated with statins for 4 weeks. In skeletal muscle, statin treatment caused dissociation of the stabilizing protein FK506 binding protein (FKBP12) from the sarcoplasmic reticulum (SR) calcium (Ca 2þ ) release channel, the ryanodine receptor 1, which was associated with pro-apoptotic signaling and reactive nitrogen species/reactive oxygen species (RNS/ ROS)Àdependent spontaneous SR Ca 2þ release events (Ca 2þ sparks). Statin treatment had no effect on Ca for statin prescription across the globe (1, 2) . However, cardiovascular benefits of statins are restricted by adverse effects that limit adherence (3, 4) and, in turn, increase cardiovascular events (5) and mortality (6) . The most common side effects and main reason for discontinuation of therapy emerge from skeletal muscle (statin myopathy or statin-associated adverse muscle symptoms). Although no strict definition of statin myopathy has been universally adopted (7-10), we use this term to encompass the full spectrum of the effects of statins on skeletal muscle.
This includes mild to moderate muscle symptoms and/or signs (myalgia: muscle pain with stiffness and weakness), as well as more severe potentially life-threatening outcomes (myositis and/or rhabdomyolysis) that are associated with raised creatine kinase (8, 11) . Although physical activity counteracts metabolic and cardiovascular diseases that are prevalent in subjects prescribed statins, exercise has been reported to exacerbate statin myopathy (12) (13) (14) (15) (16) (17) (18) (19) , which may further limit the benefits of statins in those at risk of cardiovascular disease.
Statins are inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase that limit the production of cholesterol, isoprenoids, and coenzyme Q. Despite extensive research, which has focused on calcium (Ca 2þ ) homeostasis and mitochondrial function (20) (21) (22) (23) (24) (25) , a cohesive mechanism for statin-induced myopathy is lacking. Furthermore, an understanding of why myopathy is not experienced by everyone who takes statins and the reason for its selectivity for skeletal muscle has not been fully addressed.
Using human and rodent muscle, we investigated the mechanism for statin-induced myopathy and described its interaction with voluntary moderate exercise. We revealed a mechanism by which statin treatment can make skeletal muscles susceptible to Lotteau et al.
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METHODS
STUDY APPROVAL. Anonymized vastus medialis samples were obtained from patients who were screened (and tested negative) for malignant hyperthermia. Individuals taking statins were age-and sex-matched with control subjects ( Calpain activity was assessed using the assay kit QIA120 (Merck Millipore). 
RESULTS

SUMMARY OF EXPERIMENTAL PLAN AND KEY
FINDINGS. Supplemental Table 1 provides a summary of all experiments performed, with key findings for both human and rodent preparations. 1A and 1B) . It was
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A U G U S T 2 0 1 9 : 5 0 9 -2 3 noteworthy that a robust dissociation of FKBP12 from RyR1 could be detected, although muscle biopsies were obtained from a diverse patient group ( Table 1) .
FKBP12 dissociation from RyR1 has been shown to increase spontaneous SR Ca 2þ leak, which, in turn, promotes protein degradation and programmed cell death (33) . Therefore, we next studied whether the change in the RyR complex in muscles of statintreated subjects was accompanied by indexes of pro-apoptotic signaling. For this purpose, we measured the protein expression of the inactive procaspase-3 and its cleaved active product, the proapoptotic enzyme caspase-3. Statin treatment increased caspase-3 expression in both human and rat muscles ( Figures 1C and 1D) . In rat muscle, we also measured the proportion of TUNEL positive nuclei, which is another marker for pro-apoptotic signaling, and observed a marked increase with statin treatment ( Figure 1E ). Thus, muscles from both humans and rats treated with statins showed major alterations that were potentially deleterious and might underlie (20, 21, 23) . However, all previous work has been performed on permeabilized muscle fibers, in which the constitutive inhibition of RyR1 by magnesium (37) and the dihydropyridine receptor (38) is reduced, which may mask the effects of statins. Therefore, we evaluated the effect of statin treatment on the SR Lotteau et al. Figure 3C ).
L-NAME inhibits NO and superoxide production from NOS (48), which indicates a role for NO, superoxide, and/or peroxynitrite in the spark-mediated leak.
Statin treatment has been shown to increase ROS production in skeletal muscle (25) . We showed that these ROS played a role in the SR Ca 2þ leak, in Ca 2þ spark frequency and duration between fibers from control and statin-treated rats ( Figures 3D and 3E ). 
Bidirectional
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A U G U S T 2 0 1 9 : 5 0 9 -2 3 (13, 14) and myositis (12, 15, 16) , and that statins limit training adaptations in skeletal muscle (57, 58) . Therefore, we gave statin-treated and control rats access to an in-cage running wheel, which resulted in a type of voluntary exercise similar to that recommended for human subjects prescribed statins.
CONSEQUENCES OF STATIN-INDUCED SR Ca
Rats were acclimatized to the wheel for 4 days before statin treatment commenced. Unexpectedly, the daily running distance was greater for statin-treated rats than for control rats across the 4 weeks of the study ( Figure 5A ). The larger daily running distance in the statin group was due to an increase in the number of bouts of activity ( Figure 5B ), whereas the running bout duration ( Figure 5C ) and running velocity ( Figure 5D ) were similar in the 2 groups.
In sharp contrast to the situation in muscles of sedentary subjects (see Figure 1) , binding of FKBP12 to
RyR1 showed no significant difference between muscles of statin-treated and control rats after 4 weeks of exercise ( Figures 6A and 6B) . Moreover, in the exercised state, statin treatment no longer caused a significant increase in caspase 3 expression ( Figures 6C and 6D) . Intriguingly, in the exercised state, the frequency of SR Ca 2þ sparks was lower in muscle fibers of statin-treated rats than in control rats, which contributed to a smaller spark-mediated Ca 2þ leak in this group ( Figures 6E to 6G) .
A number of studies have linked statin-induced myopathy with impaired mitochondrial biogenesis. 
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The transcriptional co-activator PGC1 is a key mediator of mitochondrial biogenesis in response to endurance exercise (59) (60) (61) . Statin treatment has been shown to decrease PGC1a mRNA expression in human and rodent fast skeletal muscle (24) ; however, no change in PGC1a protein was detected in rodent muscle (62) . We saw no impact of statin treatment on protein expression of PGC1a or HADHA (which is used as an index of mitochondrial biogenesis) either in sedentary or exercised animals ( Figures 7A to 7C) .
Together, these data show that statin treatment did not limit moderate physical activity or markers of training adaptation in skeletal muscle. Exercise reversed the statin-dependent SR Ca 2þ leak, which suggests a potentially beneficial effect.
DISCUSSION
The prevalence of statin-induced muscle symptoms varies between 7% and 29% in registries and Lotteau et al.
Statin Myopathy
A U G U S T 2 0 1 9 : 5 0 9 -2 3 observational studies (63) . Thus, most patients taking statins do not experience skeletal muscle problems.
In skeletal muscle of statin-treated humans and rats, we showed FKBP12 dissociation from RyR1, which Lotteau et al.
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